Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

The treatment procedures are required in the case of the severity of the condition. The patient then needs to go for a kidney ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Adicet Bio, Inc. (Market cap: $75.8M), a biopharmaceutical company currently rated 'FAIR' by InvestingPro's Financial Health scoring system, has announced updates on the enrollment of its clinical ...

The following is a summary of “Nomogram for predicting proliferative lupus nephritis in patients with low-level proteinuria,” ...